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Impact of this research 
We demonstrate that the sphingolipid profile in cystic fibrosis (CF) airway epithelial 
cells is abnormal due to altered function of metabolizing enzymes leading to ceramide 
accumulation and a lack of upregulation of sphingosine, which has antimicrobial 
properties, in response to Pseudomonas aeruginosa. It is possible to modulate 
ceramide levels via treatment with recombinant acid ceramidase and demonstrate 
reduced susceptibility to infection and inflammation. Acid ceramidase is already being 
used therapeutically in people with Farber Disease and therefore has translational 
potential to be repurposed to ameliorate the two pivotal features of cystic fibrosis lung 
disease, inflammation and infection. 
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Abstract 
Rationale: In cystic fibrosis the major cause of morbidity and mortality is lung disease 
characterized by inflammation and infection. The influence of sphingolipid metabolism 
is poorly understood with a lack of studies using human airway model systems. 
Objectives: To investigate sphingolipid metabolism in cystic fibrosis and the effects of 
treatment with recombinant human acid ceramidase on inflammation and infection. 
Methods: Sphingolipids were measured using mass spectrometry in fully-
differentiated cultures of primary human airway epithelial cells and co-cultures with 
Pseudomonas aeruginosa. In situ activity assays, Western blotting and quantitative 
polymerase chain reaction were used to investigate function and expression of 
ceramidase and sphingomyelinase. Effects of treatment with recombinant human acid 
ceramidase on sphingolipid profile and inflammatory mediator production were 
assessed in cell cultures and murine models. 
Measurements and Main Results: Ceramide is increased in cystic fibrosis airway 
epithelium due to differential function of enzymes regulating sphingolipid metabolism. 
Sphingosine, a metabolite of ceramide with antimicrobial properties, is not upregulated 
in response to Pseudomonas aeruginosa by cystic fibrosis airway epithelia. Tumor 
necrosis factor receptor 1 is increased in cystic fibrosis epithelia and activates NF-κB 
signaling, generating inflammation. Treatment with recombinant human acid 
ceramidase, to decrease ceramide, reduced both inflammatory mediator production 
and susceptibility to infection. 
Conclusions: Sphingolipid metabolism is altered in airway epithelial cells cultured 
from people with cystic fibrosis. Treatment with recombinant acid ceramidase 
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ameliorates the two pivotal features of cystic fibrosis lung disease, inflammation and 
infection, and thus represents a therapeutic approach worthy of further exploration. 
[Word count 248] 
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Introduction 
Cystic fibrosis (CF) is among the most common life-limiting genetic disorders 
worldwide(1, 2). The major cause of morbidity and mortality in CF is lung disease 
characterized by neutrophilic inflammation, mucus retention and susceptibility to 
endobronchial infection with, in particular, Staphylococcus aureus and Pseudomonas 
aeruginosa(1). A cycle of inflammation and infection ensues, resulting in progressive 
bronchiectasis. Several hypotheses have been proposed to explain the 
pathophysiology seen in CF lung disease, including abnormal volume, pH and 
electrolyte content of the airway surface liquid(3-8). However, the precise mechanisms 
are not fully elucidated and multiple processes that impact on inflammation and 
defense against infection are likely to be involved.  
Sphingolipids form membrane domains that can interact to alter the function of 
membrane components and modulate a diverse range of biologically important 
processes(9). Sphingolipids have previously been linked to CF pathophysiology. 
Increased levels of ceramide have been identified in the airway epithelium of CF 
murine models that, when normalized, reduced inflammation and susceptibility to P. 
aeruginosa infection(10, 11). Raised ceramide has also been found in the epithelium 
of lungs removed at the time of transplantation from people with CF(12). Reports have 
suggested that relative concentrations of ceramides may be important, with different 
chain lengths over- and under-represented in the blood of people with CF and murine 
models(13-15). Lipidomic analysis of bronchoalveolar lavage (BAL) fluid has recently 
demonstrated an altered profile in CF(16, 17). 
Studies using human airway model systems are lacking, representing an important 
gap. In part, this is due to the fact that fully differentiated cultures of primary human 
 4 
 
bronchial airway epithelial cells from people with CF present technical challenges (18). 
In the context of sphingolipid metabolism, this human model allows investigation of 
underlying mechanisms and refinement of targets for intervention.  
Here we investigate the metabolism of ceramides using primary human airway 
epithelial cell cultures, BAL fluid and murine models. We describe how the function of 
key enzymes involved in ceramide metabolism - acid sphingomyelinase (which 
converts sphingomyelin to ceramide) and acid ceramidase (which converts ceramide 
to sphingosine) - is altered in CF. This promotes accumulation of ceramides that in turn 
leads to inflammation (generated via tumor necrosis factor receptor 1 (TNFR1) 
activation and NF-κB signaling), and susceptibility to infection (due to lack of 
upregulation of sphingosine). Treatment of airway epithelial cell cultures with 
recombinant human acid ceramidase (rhAC) decreased inflammation and infection. 
Furthermore, in murine models, nebulization of rhAC reduced airway inflammation, 
suggesting a therapeutic approach worthy of further investigation. 
 
 
Methods 
Primary airway epithelial cell culture and culture treatment  
Primary bronchial epithelial cells were cultured at an air liquid interface (ALI) as 
previously described(18). Clinical characteristics of the patients studied are in Table 
E1 in the online data supplement. All cultures generated cilia, produced mucus and 
had a trans-epithelial resistance >250 Ω*cm2.  
 5 
 
For co-culture experiments ALI cultures were transitioned to antibiotic-free medium, 
and 1x105 colony forming units of P. aeruginosa (PA01) in 100 μL phosphate-buffered 
saline were added to the apical surface, and incubated for 24 hours. In specific 
experiments, cultures were treated apically for 1 hour with: 100 μL of rhAC (20 μg/mL), 
generated as described previously(19); the highly selective and potent cRel inhibitor 
IT 901 (2 μM) for 24 hours; or the CF transmembrance conductance regulator (CFTR) 
modulators ivacaftor or tezacaftor-ivacaftor in combination (each 5 μM) for 48 hours 
with dose refreshed after 24 hours. 
Detailed methods, including sample preparation for analysis, and standard 
methodologies (Western blotting, real-time qPCR and ELISA) are provided in the 
online data supplement. 
Analysis of sphingolipid profile of cell cultures by mass 
spectrometry  
Calibration curves for all assayed ceramide and sphingosine species were constructed 
using appropriate standards. All standards and samples were analyzed in triplicate with 
the ABSciex QTrap 4000 system, using a 3-scan event methodology to reduce matrix 
noise. For selectivity the mass tolerance for each ion was set to within 0.01 m/z, which 
allowed for accurate quantification. 
BAL ceramide measurement 
For ceramide determination, a ceramide hydrolysis buffer (0.2 M citric/phosphate 
buffer, 0.3 M NaCl and 0.2 mg/ml of recombinant acid ceramidase) was mixed with the 
total lipid extract solution (1:1,v/v) and incubated at 37 °C for 1 hour. Cell-free 
supernatant samples were analyzed using an Acquity H-Class UPLC system equipped 
with a Waters Acquity UPLC BEH RP18 column.  
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Ceramidase and sphingomyelinase functional in situ assays 
100 μL of buffered solution containing either BODIPY® TR Ceramide or BODIPY® FL 
C12-Sphingomyelin at a 1:2000 dilution was applied to the apical surface of ALI 
cultures. The lipid fraction was isolated as described in the online data supplement and 
samples were separated by thin layer chromatography with chloroform:methanol (5:1 
v/v).  
Mice studies 
Two different Cftr mutant mouse strains and their respective syngeneic littermates 
were used. Cftrtm1Unc-Tg(FABPCFTR) (abbreviated CftrKO) Jaw mice are genetically 
deficient for the murine equivalent to human CFTR (Cftr), but express human CFTR in 
the gut under control of a fatty acid binding protein promoter to prevent acute intestinal 
obstruction. B6.129P2(CF/3)-CftrTgH(neoim)Hgu (abbreviated CftrMHH) congenic mice were 
also used that have a low residual activity of Cftr allowing normal development and 
feeding. 
Nebulization of recombinant human acid ceramidase 
CftrKO and CftrMHH mice were nebulized with rhAC 200 μg diluted in 800 μL 0.9% NaCl 
solution using Pari boy nebulizer apparatus over 10 minutes. rhAC was nebulized on 
3 consecutive days when mice were 24 weeks old. The trachea was removed 6 hours 
after the last inhalation for further analysis as described in the online data supplement. 
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Results 
Ceramide metabolism is dysregulated in cystic fibrosis airway epithelial cells 
Mass spectrometry was used to investigate the ceramide profile in primary bronchial 
epithelial cells isolated from people with CF or controls, and fully differentiated at an 
ALI. Clinical characteristics of the patients studied are in Table E1 in the online data 
supplement. Under basal conditions, total levels of ceramide were increased in CF 
cultures (Fig 1a) with similar levels of sphingosine, a key metabolite of ceramide, in CF 
and non-CF cultures (Fig 1b). There was increased C16 and C22 ceramide in CF 
cultures (Fig 1c). In murine models, normalization of sphingolipids has been associated 
with reduction in susceptibility to P. aeruginosa, the most significant respiratory 
pathogen in CF(10). We therefore investigated the ceramide profile of cultures 
following co-culture with live P. aeruginosa. In both CF and non-CF cultures total 
ceramide was increased following exposure to P. aeruginosa (Fig 1a), with statistically 
significant increases in C16, C20 and C22 observed in CF cultures only (Fig 1c). An 
increase in sphingosine occurred in non-CF cultures exposed to P. aeruginosa (Fig 
1b). However, in CF cultures P. aeruginosa did not induce changes. Sphingolipids are 
pivotal constituents of plasma membranes with enriched domains crucial for 
modulating cellular functions. We therefore also measured sphingolipid concentrations 
in plasma membrane fractions and found a similar pattern to that in whole cell lysates 
for ceramide and sphingosine (Figs 1d-f). The proportion of ceramide in membrane 
fractions was comparable across all experiments (Fig 1g). An increase in sphingosine 
occurred in non-CF cultures exposed to P. aeruginosa in plasma membrane fractions 
(Fig 1e) with an increase in percentage present in the plasma membrane (Fig 1h). 
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Similar to results in whole cell lysates, P. aeruginosa did not induce changes in plasma 
membrane sphingosine in CF cultures (Figs 1e and 1h).  
Collectively, these data suggest that ceramide accumulates in human CF airway 
epithelial cells with a distinct profile of individual species present, including both long 
chain and very long chain ceramides. In response to P. aeruginosa non-CF cultures 
upregulate sphingosine, an effect not seen in CF cultures.  
 
Ceramide is increased in BAL fluid from children and young people with cystic 
fibrosis 
To test whether the situation in vitro was mirrored in situ, we measured total ceramide 
in BAL fluid collected during clinically-indicated bronchoscopies from children and 
young people with CF and an age-matched comparator group who do not have CF but 
underwent investigation for respiratory problems (clinical details are in Table E1 in the 
online data supplement). Levels of ceramide were increased in the CF group (Fig 2a).  
 
In cystic fibrosis epithelia there is decreased function of ceramidase and 
increased function of sphingomyelinase  
To investigate potential mechanisms responsible for ceramide accumulation we 
measured functional enzyme activity at the apical surface of cell cultures. Total 
ceramidase activity was reduced in CF cultures (Fig 3a). Acid ceramidase protein and 
ASAH1 (coding for acid ceramidase) gene expression were decreased in CF cells 
compared to non-CF (Figs 3b and c). Following co-culture with P. aeruginosa there 
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was an increase in acid ceramidase protein and ASAH1 gene expression in non-CF 
cultures with a smaller increase observed in CF cultures (Figs 3b and c). 
Conversely, sphingomyelinase activity was increased (Fig 3d) in CF cultures. 
However, there was no difference in acid sphingomyelinase protein or the expression 
of the SMPD1 (coding for acid sphingomyelinase) gene between any cell type or 
treatment (Figs 3e and f).  
Together, these data suggest that a combination of reductions in expression and 
function of acid ceramidase (which converts ceramide to sphingosine) and an increase 
in sphingomyelinase (which converts sphingomyelin to ceramide) function serve to 
promote the accumulation of ceramide observed in human CF airway epithelium.  
 
Treatment with recombinant human acid ceramidase reduces levels of 
ceramide in cystic fibrosis airway epithelia 
Based on Figure 3, we assessed the capacity for rhAC to modulate ceramide levels in 
human airway epithelial cells. rhAC has recently been developed as an enzyme 
replacement therapy for Farber disease(20-22). Initial experiments established no 
cytotoxic effect of rhAC on airway epithelial cell cultures (Figs E2a and b in the online 
data supplement). A single treatment of CF cultures with rhAC reduced ceramide and 
restored levels close to those seen in non-CF cultures (Fig 4a). For sphingosine, no 
statistically significant differences were detected at the whole cell level (Fig 4b). 
Treatment with rhAC reduced C16, C22 and C24 ceramide (Fig 4c). In plasma 
membrane fractions, a similar reduction in total ceramide was observed (Fig 4d) along 
with an increase in sphingosine levels (Fig 4e) that was statistically significant in non-
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CF cultures. At the individual species level, only C24 ceramide was statistically 
significantly reduced (Fig 4f). Following rhAC treatment the proportion of ceramide in 
the plasma membrane was unchanged (Fig 4g) and the proportion of sphingosine 
present in the plasma membrane in both CF and non-CF cultures was increased (Fig 
4h). 
 
Inflammatory responses are reduced following treatment with recombinant 
human acid ceramidase 
Neutrophilic airway inflammation is a pivotal part of CF lung disease 
pathophysiology(1). In view of the role of sphingolipids in modulating inflammatory 
responses we investigated the effect of rhAC treatment on inflammatory mediator 
production at the apical surface of airway epithelial cell cultures(9). At baseline, 
increased secretion of IL-8, IL-1β and TNFα (Figs 5a-c), was observed in CF cultures, 
with no statistically significant differences seen in IL-4 or IL-6, (Figs E3a-b in the online 
data supplement). Application of rhAC resulted in significantly reduced secretion of IL-
8 in CF cultures, to levels comparable with control non-CF cultures, and this effect was 
maintained for 5 days following a single treatment (Fig 5a). A similar, though less 
marked, effect of rhAC was observed for IL-1β, TNFα (Figs 5b and c) and IL-6 (Fig E3a 
in the online data supplement). Comparison was made with the effect of modulating 
CFTR function in CF cultures homozygous for F508del with ivacaftor or tezacaftor-
ivacaftor. Again, treatment with rhAC reduced IL-8 production with a small, but not 
statistically significant, reduction seen with tezacaftor-ivacaftor and no synergistic 
effect with rhAC and tezacaftor-ivacftor (Fig 5d). 
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To further investigate the potential for rhAC as an anti-inflammatory therapy in CF, we 
examined the effect of nebulized rhAC on airway inflammation in two different CF 
murine models. Cftrtm1Unc-Tg(FABPCFTR) (CftrKO) mice are genetically deficient for the 
murine equivalent to human CFTR (Cftr), but express human CFTR in the gut under 
control of a fatty acid binding protein promoter to prevent acute intestinal obstruction. 
In contrast, B6.129P2(CF/3)-CftrTgH(neoim)Hgu (CftrMHH) congenic mice have a low 
residual activity of Cftr allowing normal development and feeding. Increased numbers 
of neutrophils and macrophages were observed in the lungs of CF mice (Figs 6a and 
b). This was associated with increased ceramide levels (Fig E4a in the online data 
supplement). Nebulization of rhAC to mice daily for 3 days reduced neutrophil and 
macrophage numbers towards wild type levels (Figs 6a and b).  
These data suggest that treatment with rhAC reduces the production of several key 
pro-inflammatory cytokines and chemokines by CF airway epithelial cell cultures. 
Furthermore, nebulization of rhAC in two different murine models was associated with 
a reduction in cellular markers of lung inflammation. 
 
Inflammatory responses are driven by altered tumor necrosis factor receptor 1 
expression and NF-κB activation 
Changes in the lipid composition of plasma membranes can significantly alter receptor 
expression and downstream signaling events(11, 23). Sphingolipid-enriched 
membrane domains have been shown to be essential for TNFR1 activation and 
subsequent NF-κB signaling(24). We investigated TNFR1 expression in CF cultures 
and found it to be increased compared to non-CF cultures (Figs 7a and b). This 
reduced following treatment with rhAC (Figs 7a and b). These findings were confirmed 
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by Western blotting for TNFR1 in plasma membrane fractions (Fig E5 in the online 
data supplement). To investigate downstream signaling from TNFR1 we investigated 
expression and nuclear localization of NF-κB subunit cRel (Figs 7c and d). Co-culture 
with P. aeruginosa resulted in an increase in the nuclear localization of cRel in CF 
cultures. Treatment with rhAC increased cytoplasmic cRel, with a corresponding 
reduction in nuclear localization of cRel (Figs 7c and d). Use of a specific cRel inhibitor 
reduced IL-8 production (Fig 7e). In human airway tissue sections (clinical details are 
shown in Table E1 in the online data supplement), significantly more cRel was localized 
in the nucleus of epithelial cells from people with advanced CF lung disease compared 
to unused donor lungs (Figs 7f-h). Due to TNFR1 also being expressed at the 
basolateral membrane of airway epithelial cells we measured TNFa in the basolateral 
medium in the experiments shown in Fig 5c. Levels of TNFa were higher in the 
basolateral medium than in the apical washes (Fig E3c). 
These data suggest that CF epithelia have increased TNFR1 expression that reduces 
following treatment with rhAC and the decrease in ceramide levels. Consequently, 
enhanced NF-κB activation is observed in CF epithelia with increased nuclear 
localization of cRel, which also reduces with rhAC treatment. 
 
Treatment with recombinant human acid ceramidase reduces susceptibility to 
infection 
Previous work has shown that reduction of ceramide in the airways of CF mice is 
associated with a reduction in susceptibility to infection(10, 11). We therefore 
examined effects of rhAC treatment on infection in primary human airway epithelial 
cells using two different methods.  
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Firstly, heat-killed, fluorescently labeled S. aureus were added to the apical surface of 
differentiated cultures. Increased numbers of S. aureus remained adherent to the 
surface of CF cultures, suggestive of an increased susceptibility to colonization (Figs 
8a and b). Treatment with rhAC reduced the adherence of S. aureus to CF cultures 
(Figs 8a and b).  
Secondly, we investigated defense against live P. aeruginosa. Increased viable 
bacteria were isolated from the surface and lysates of CF cultures (Figs 8c and d). 
Treatment with rhAC reduced the number of viable P. aeruginosa recovered from the 
apical surface of cultures (Fig 8c), while no significant reduction in bacteria internalized 
by CF cultures was observed (Fig 8d). 
 
 
Discussion 
Through mass spectrometry analysis of differentiated primary airway epithelial cell 
cultures we have shown, and quantified, an altered ceramide profile in human CF 
epithelia. Increased ceramide was also detected in BAL fluid from children and young 
people with CF. This supports previous observations made in some murine models 
and agrees with immunohistochemistry performed on the bronchial epithelium of 
explanted advanced CF lung disease tissue (10, 12, 13). 
Previous studies of sphingolipids in CF, using different models and techniques, have 
found varying results(15). In homogenized explanted lung tissue (containing multiple 
cell types and representing end-stage disease) increased C16, C18 and C20, but not 
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C22, ceramide species were observed(12). In contrast, a cell line model transfected 
with an antisense CFTR construct demonstrated reduced levels of C18, but increased 
levels of C22, C24 and C26(25). Findings in another CF murine model and the 
peripheral blood of people with CF have suggested a reduction in C24 ceramide and 
increase in C16(13, 15). Here, using a fully differentiated model in primary human 
epithelial cells we found increased C16 and C22 in whole cell lysates and increased 
C24 in the plasma membrane. These ceramide chain lengths and their metabolites are 
known to be involved in inflammation and apoptosis(9, 12, 15, 26-31).  
Data presented here suggest that ceramide accumulates in CF airway epithelia due to 
differential function of enzymes. Decreased ceramidase function combined with 
increased sphingomyelinase activity favor increased ceramide accumulation. Western 
blot and gene expression analysis further showed that the decreased ceramidase 
activity was due to reduced acid ceramidase expression. This agrees with work in CF 
murine models showing that b1-integrin is trapped in the apical membrane of airway 
epithelial cells, downregulating acid ceramidase expression(11). 
In the case of acid sphingomyelinase we found expression to be unchanged in CF 
epithelia. The reason for the altered activity of acid sphingomyelinase remains 
uncertain. Under in vitro conditions acid sphingomyelinase is a much more active 
enzyme than acid ceramidase (i.e., has a 10-fold or greater capacity to hydrolyze 
sphingomyelin compared with the ability of acid ceramidase to hydrolyze 
ceramide)(32). One possible explanation for reduced activity is that acid 
sphingomyelinase function is known to be pH dependent (activity increases as pH 
lowers to an optimum of around 5)(33, 34). The pH of the airway surface liquid in CF 
remains keenly debated, however, there is some evidence to suggest that homeostasis 
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is disordered and that the pH is lowered(3, 4, 35-38). Another potential explanation, is 
that acid ceramidase and acid sphingomyelinase are known to exist in a complex with 
inter-connected functions(19). It is therefore possible that reduced acid ceramidase 
expression may lead to a conformational change in acid sphingomyelinase and further 
enhanced enzyme activity.  
Treatment of CF cultures with rhAC decreased ceramide close to levels present in non-
CF cultures and reduced secretion of inflammatory mediators. Nebulization of rhAC in 
CF mouse models also reduced lung inflammation. We found evidence of neutrophilic 
inflammation in the lungs of CftrKO and CftrMHH mice. A constitutive increase in 
expression of IL-1 and the mouse homolog of IL-8, keratinocyte-derived chemokine, 
has been shown in lung homogenates from these mice (10). Reduction of ceramide 
levels (genetically by crossing with acid sphingomyelinase knock out animals or 
pharmacologically via amitriptyline treatment) has also been shown to lead to a 
reduction in neutrophilic inflammation(10). Our work would have been strengthened by 
measurement of key cytokines and chemokines in the murine lung, histological 
assessment of neutrophil and macrophage distribution, and by studying in vivo 
responses to airway infection. 
There are divergent findings in the literature around the existence of a pro-
inflammatory state in the CF airway in the absence of identifiable infection, with some 
evidence to support this concept from BAL studies in young children but varied findings 
in other studies and animal models(1, 39-44). In our primary human airway epithelial 
model we found increased production of several pro-inflammatory mediators in 
cultures derived from adults with advanced CF lung disease. The effects of altered 
membrane microdomain abundance on relative fluidity and stability of transmembrane 
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receptors involved in inflammatory responses and activity of ion channels remains 
poorly understood(15, 45, 46). Notably, Abu-Arish et al. recently demonstrated that 
epithelial cells respond to secretagogues by forming clusters of CFTR in ceramide-rich 
membrane microdomains via an acid sphingomyelinase-dependent mechanism to 
increase transepithelial secretion(47). We found that reducing ceramide in CF 
epithelial cells, via rhAC treatment, was associated with reduced TNFR1 expression, 
decreased cRel nuclear localization and less IL-8 production. It is recognized that 
activation of NF-κB results in IL-8 production, however, epigenetic factors and mRNA 
stability also influence this process and how a change in sphingolipid profile impacts 
on these is yet to be elucidated (48-50). 
Relatively low levels of TNFa, in the range of 1-2 pg/mL in apical washings and 5-9 
pg/mL in basolateral medium, were measured in unstimulated cultures, in keeping with 
those reported in the literature (51). However, epithelial cells are not the only source 
of TNFa in the CF lung, with  reports of production by macrophages and neutrophils 
(52). Several studies have measured levels of TNFa in airway samples from people 
with CF. For example, mean levels of 130 and 400 pg/mL have been measured in 
sputum and BAL fluid respectively, with higher concentrations during pulmonary 
exacerbations(52-54). 
We also found increased susceptibility to infection in CF cultures that was reduced by 
rhAC treatment. Sphingosine, which is generated from ceramide by acid ceramidase, 
is known to have antimicrobial properties and has been found to be deficient in the 
airway of CF murine models(11). We did not detect differences in sphingosine between 
CF and non-CF human cultures at baseline. However, unlike non-CF cells, on 
exposure to P. aeruginosa CF epithelial cells did not upregulate levels of sphingosine 
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in the plasma membrane. We propose that this represents a potentially important host-
defense mechanism, dysfunction of which may contribute to the susceptibility to 
respiratory infection seen clinically in people with CF. Treatment with rhAC did increase 
plasma membrane sphingosine in cell cultures but this effect was only statistically 
significant in non-CF cultures. A potential explanation for this is that sphingosine 
produced following rhAC treatment may be rapidly metabolized. In a mouse model of 
Farber disease intraperitoneal rhAC treatment markedly reduced ceramide levels but 
sphingosine increased to a lesser extent, especially so in the lung compartment(22). 
When considering the proportion of sphingosine in the plasma membrane there was a 
significant increase in both CF and non-CF cultures with rhAC treatment. This localized 
increase in sphingosine may account for the effect of rhAC treatment on reducing 
bacterial adherence to the apical plasma membrane, but not internalization. 
Limitations of our infection work are that we used a laboratory strain of P. aeruginosa 
rather than a clinical isolate and did not work with live S. aureus. Proof of principle data 
were generated to investigate the effects of acute rhAC treatment on inflammation and 
infection. To advance along a translational path further evidence will likely need to be 
generated for longer-term treatment and efficacy in larger animal models prior to 
experimental medicine studies in humans. 
Collectively, our work supports the concept that disordered sphingolipid metabolism is 
involved in CF lung disease pathogenesis - linking to both inflammation and infection. 
Restoring acid ceramidase activity with rhAC treatment therefore represents an 
intriguing novel potential approach to target these two key pathological processes in 
the airways of people with CF. Despite exciting developments in the field of CFTR 
modulators there remains an unmet need to develop therapies that ameliorate ongoing 
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problems with inflammation and infection(55). It is also unlikely that any single 
medication will fully treat the complex pathophysiology of CF lung disease and highly 
probable that people with CF will continue to be treated with a combination of drugs in 
the future. The fact that rhAC is currently being developed as a treatment for patients 
with Farber disease highlights the potential of re-purposing this drug for CF(56, 57). 
Towards this end, we have demonstrated that rhAC may be delivered in nebulized form 
to mice and has important effects in vivo. 
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Figure Legends 
Figure 1 – Ceramide and sphingosine levels in cystic fibrosis and non-cystic 
fibrosis fully differentiated primary human airway epithelial cell cultures at 
baseline and in response to Pseudomonas aeruginosa. Whole cell lysates of cystic 
fibrosis (CF) and non-CF cultures at baseline and after co-culture with Pseudomonas 
aeruginosa (PA), levels of total ceramide (a) and sphingosine (b). Radar charts (c) of 
individual ceramide species (fmole/mg protein). Plasma membrane (PM) fractions of 
cultures were isolated at baseline and after co-culture with P. aeruginosa, allowing 
determination of total ceramide (d) and sphingosine (e) levels. Individual ceramide 
species (f), displayed as radar charts (fmole/mg protein). The proportion of ceramide 
in plasma membranes (as a fraction of total cellular ceramide) is shown in panel (g) 
and equivalent for sphingosine in (h). Throughout, n=6 separate experiments from 
individual donors. Cultures were lysed and fractionated into whole cell and plasma 
membrane fractions after 28 days at air liquid interface and full differentiation. 
Individual data points are presented along with the mean (horizontal line) and ± 
standard deviation (error bars). For statistical tests used see the online data 
supplement *P<0.05, **P<0.01, ***P<0.001. 
 
Figure 2 - Ceramide levels in BAL fluid from children and young people. Levels 
of ceramide in BAL fluid collected during clinically indicated bronchoscopies from 
children and young people with cystic fibrosis (CF) and children who do not have CF 
but underwent a bronchoscopy for investigation of respiratory problems. Groups were 
matched for age (see Table E1 in the online data supplement). Individual data points 
are presented along with the mean (horizontal line) and ± standard deviation (error 
bars). An unpaired t-test was used to determine significance *P<0.05. 
 
Figure 3 – Acid ceramidase and acid sphingomyelinase expression and function 
in cystic fibrosis and non-cystic fibrosis airway epithelial cell cultures. (a) Apical 
surface activity of ceramidase (Cer), as determined by percentage of fluorescently 
labeled ceramide processed into sphingosine. (b) Levels of acid ceramidase (AC) 
protein in cystic fibrosis (CF) and non-CF cultures at baseline and after co-culture with 
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Pseudomonas. aeruginosa (PA), displayed as change relative to untreated non-CF 
cultures. Representative blots are shown for AC, (methods for full-length blots are in 
the online data supplement, with details of loading controls shown in Figure E1). (c) 
Gene expression of ASAH1 (coding for acid ceramidase) at baseline in CF and non-
CF cultures and after co-culture with P. aeruginosa, displayed as fold change relative 
to untreated non-CF cultures. (d) Apical surface activity of sphingomyelinase (Sph), as 
determined by percentage of fluorescently labeled sphingomyelin processed into 
ceramide. (e) Levels of acid sphingomyelinase (ASM) protein, displayed as change 
relative to untreated non-CF cultures. Representative blots are shown for ASM 
(methods for full-length blots are in the online data supplement, with details of loading 
controls shown in Figure E1). (f) Gene expression of SMPD1 (coding for acid 
sphingomyelinase), displayed as fold change relative to untreated non-CF cultures. 
For loading controls, antibody, and primer and reaction details see Fig E1 and Tables 
E2, E3 and E4 in the online data supplement. Throughout, n=6 separate experiments 
from individual donors. Individual data points are presented along with the mean 
(horizontal line) and ± standard deviation (error bars). For statistical tests used see the 
online data supplement *P<0.05, **P£0.01. 
 
Figure 4 – Effect of recombinant human acid ceramidase treatment on ceramide 
and sphingosine profile of cystic fibrosis and non-cystic fibrosis airway 
epithelial cell cultures. Whole cell lysates of cystic fibrosis (CF) and non-CF cultures 
at baseline and after treatment with recombinant human acid ceramidase (rhAC); 
levels of total ceramide (a) and sphingosine (b). Individual ceramide species (c), 
displayed as radar charts (fmol/mg protein). Plasma membrane fractions of CF and 
non-CF cultures at baseline and after treatment with rhAC - levels of total ceramide (d) 
and sphingosine (e). Individual ceramide species (f), displayed as radar charts 
(fmole/mg protein). Proportion of ceramide in plasma membranes (PM) (as a fraction 
of total cellular ceramide) is shown in panel (g) and the equivalent for sphingosine in 
(h). Throughout, n=6 separate experiments from individual donors. Cultures were lysed 
and fractionated into whole cell and plasma membrane fractions after 28 days at air 
liquid interface and full differentiation. Individual data points are presented along with 
the mean (horizontal line) and ± standard deviation (error bars). For statistical tests 
used see the online data supplement *P<0.05, **P£0.01. 
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Figure 5 – Effect of recombinant human acid ceramidase treatment on 
inflammatory mediator production by cystic fibrosis and non-cystic fibrosis 
airway epithelial cell cultures. Time course of apical secretion of (a) IL-8, (b) IL-1β, 
and (c) TNFα from cystic fibrosis (CF) and non-CF cultures at baseline and after a 
single treatment with recombinant human acid ceramidase (rhAC). Apical secretion of 
IL-8 (d) from cultures following pre-treatment with combinations of ivacaftor, tezacaftor-
ivacaftor and rhAC. For (a) through (c) n=6 separate experiments, n=4 for (d), CF group 
F508del/F508del genotype, from individual donors. Data are presented as mean with 
standard deviation for (a) through (c); for (d) individual data points are presented along 
with the mean (horizontal line) and ± standard deviation (error bars). For statistical 
tests used see the online data supplement *P<0.05, **P£0.01, ***P£0.001 and ns non-
significant P³0.05. 
 
Figure 6 – Effect of recombinant human acid ceramidase treatment on lung 
inflammation in murine models. Number of (a) neutrophils and (b) macrophages in 
the submucosa of distal large bronchi in lung sections from wild type (WT), Cftrko and 
CftrMHH mice at baseline and following nebulization daily for 3 days with recombinant 
human acid ceramidase (rhAC). Throughout, n=6 mice in each group. Individual data 
points are presented along with the mean (horizontal line) and ± standard deviation 
(error bars). For statistical tests used see the online data supplement ***P£0.001. 
 
Figure 7 – Tumor Necrosis Factor Receptor 1 expression and cRel localization 
in cystic fibrosis airway epithelial cell cultures and lung tissue sections. 
Expression of Tumor Necrosis Factor Receptor 1 (TNFR1) in cystic fibrosis (CF) and 
non-CF cultures with and without recombinant human acid ceramidase (rhAC) 
treatment as assessed by (a) immunohistochemistry (with quantification of apical 
mean pixel intensity (MPI) in (b)). cRel expression in CF and non-CF cultures in 
response to Pseudomonas aeruginosa (PA) co-culture in the presence or absence of 
rhAC in (c) cytoplasmic and (d) nuclear fractions. Representative blots are shown for 
both (methods are in the online data supplement, with details of loading controls 
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shown in Figure E1). (e) Apical IL-8 secretion in the presence or absence of a 
specific cRel inhibitor (Inh). (f) Expression and localization of cRel in airway 
epithelium in airway tissue sections from people with advanced CF lung disease and 
unused donor lungs (non-CF) with quantification of (g) whole cell and (h) nuclear 
localization. For (a) through (d) n=6 separate experiments, n=5 for (e) and n=4 for (f) 
through (h), all from individual donors, see Table S1 in the online data supplement for 
clinical details. Data are presented as mean with standard deviation for (b), (g) and 
(h); for (c) through (e) individual data points are presented along with the mean 
(horizontal line) and ± standard deviation (error bars). For statistical tests used see 
the online data supplement *P<0.05, **P£0.01. 
 
Figure 8 – Effect of recombinant human acid ceramidase treatment on infection 
in cystic fibrosis airway epithelial cell cultures. Number of fluorescently labeled 
heat-killed Staphylococcus aureus retrieved from apical surface washes (a), and 
adherent to apical surface (b) in cystic fibrosis (CF) and non-CF fully differentiated 
cultures with and without prior recombinant human acid ceramidase (rhAC) treatment. 
For representative images see Fig E6 in the online data supplement. Colony forming 
unit (CFU) counts of Pseudomonas aeruginosa isolated from (c) apical surface washes 
and (d) whole cell lysates (following washing, suggesting internalization) from CF and 
non-CF cultures with and without prior rhAC treatment. Live P. aeruginosa were added 
to the apical surface of cultures and allowed to proliferate for 24 hours. Throughout 
n=6 separate experiments. Individual data points are presented along with the mean 
(horizontal line) and ± standard deviation (error bars). For statistical tests used see the 
online data supplement *P<0.05, **P£0.01. 
 
Figure 9 – Proposed model of how altered sphingolipid metabolism in cystic 
fibrosis airway epithelia may result in increased inflammation and susceptibility 
to infection. (a) In non-cystic fibrosis epithelia acid ceramidase (AC) maintains the 
balance of ceramide (Cer.) and sphingosine (Sph.). Normal levels of ceramide do not 
promote a pro-inflammatory environment and in response to P. aeruginosa levels of 
sphingosine are up-regulated. (b) In cystic fibrosis (CF) epithelia AC activity is deficient 
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in both expression and activity which, in combination with alterations in acid 
sphingomyelinase activity, leads to the accumulation of ceramide. Raised ceramide is 
associated with increased tumor necrosis factor receptor 1 (TNFR) expression, 
enhanced NF-κB activation and nuclear localization of cRel. This promotes the 
secretion of pro-inflammatory cytokines such as IL-8, IL-1β and TNFα. In conjunction 
with excessive recruitment of immune cells, which also produce pro-inflammatory 
mediators, a positive feedback loop emerges in the cystic fibrosis airway. Cystic 
fibrosis epithelia do not up-regulate sphingosine in response to P. aeruginosa, 
increasing susceptibility to infection, which further contributes to the pro-inflammatory 
environment. Treatment with recombinant human acid ceramidase (rhAC) reduces 
ceramide and increases sphingosine, ameliorating these effects.  
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Figures 
Figure 1 – Ceramide and sphingosine levels in cystic fibrosis and non-cystic 
fibrosis fully differentiated primary human airway epithelial cell cultures at 
baseline and in response to Pseudomonas aeruginosa. 
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Figure 2 - Ceramide levels in BAL fluid from children and young people. 
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Figure 3 – Acid ceramidase and acid sphingomyelinase expression and function 
in cystic fibrosis and non-cystic fibrosis airway epithelial cell cultures. 
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Figure 4 – Effect of recombinant human acid ceramidase treatment on ceramide 
and sphingosine profile of cystic fibrosis and non-cystic fibrosis airway 
epithelial cell cultures. 
 
 38 
 
 
  
 39 
 
Figure 5 – Effect of recombinant human acid ceramidase treatment on 
inflammatory mediator production by cystic fibrosis and non-cystic fibrosis 
airway epithelial cell cultures. 
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Figure 6 – Effect of recombinant human acid ceramidase treatment on lung 
inflammation in murine models. 
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Figure 7 – Tumor Necrosis Factor Receptor 1 expression and cRel localization 
in cystic fibrosis airway epithelial cell cultures and tissue sections
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Figure 8 – Effect of recombinant human acid ceramidase treatment on infection 
in cystic fibrosis airway epithelial cell cultures. 
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Figure 9 – Proposed model of how altered sphingolipid metabolism in cystic 
fibrosis airway epithelia may result in increased inflammation and susceptibility 
to infection. 
 
